Jun 01, 2020
Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta
May 20, 2020
Mitsubishi Tanabe Pharma America Announces Launch Of The JourneyMate Program, Offering Live Nurse Educational Phone Support For ALS Patients And Caregivers
May 05, 2020
Mitsubishi Tanabe Pharma America Marks Third Anniversary Of FDA Approval And Reports More Than 5,000 Patients With ALS Treated With RADICAVA® (edaravone)
Apr 29, 2020
Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Quebec
Apr 27, 2020
Global Diabetic Nephropathy Pipeline Assessment, H1 2020: Therapeutics, Developments, Products, Drugs, Players
Dec 04, 2019
Mitsubishi Tanabe Pharma America to Present Real-World Data on RADICAVA® (edaravone) for ALS at the 30th International Symposium on ALS/MND
Nov 25, 2019
Mitsubishi Tanabe Pharma America Announces Initiation of Phase 3 Study Evaluating Investigational Oral Formulation of Edaravone for ALS
Nov 05, 2019
Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (Edaravone) for Amyotrophic Lateral Sclerosis
Oct 23, 2019
Update on Canadian Product Availability
Sep 26, 2019
Mitsubishi Tanabe Pharma America Announces Appointment Of Gustavo A. Suarez Zambrano, M.D., As Vice President, Medical Affairs
Sep 23, 2019
Mitsubishi Tanabe Pharma Corporation Group Announces Presentation of Patient-Reported Results from Phase 2 ND0612 Study at International Congress of Parkinson's Disease and Movement Disorders
Sep 20, 2019
Mitsubishi Tanabe Pharma America To Present On ALS Clinical Programs At 2019 Muscle Study Group Annual Scientific Meeting
Aug 28, 2019
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations
Aug 08, 2019
More Than 4,000 U.S. Patients With ALS Treated With RADICAVA® (edaravone) In Two Years Since Availability, Mitsubishi Tanabe Pharma America Reports
May 06, 2019
MTPA Announces Nationwide Database Of ALS Infusion Services To Help Patients And Caregivers Identify Local Providers
May 03, 2019
Oxford BioDynamics Joins ALS Biomarker Study Sponsored By Mitsubishi Tanabe Pharma America
May 02, 2019
Post-Hoc Analyses of RADICAVA® (edaravone) Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency
Apr 26, 2019
BioInvent Receives EUR0.75 Million Milestone Under Mitsubishi Tanabe Pharma Partnership
Apr 11, 2019
Mitsubishi Tanabe Pharma America to Highlight ALS Research Initiatives at 2019 MDA Clinical & Scientific Conference
Mar 01, 2019
Mitsubishi Tanabe Pharma America Appoints Sam Shum as Vice President of Operations and Strategy